Reference is made to the
stock exchange notice released on 20 September 2016 by Hofseth
BioCare ASA ("HBC" or the "Company") regarding the general
meeting's decision to resolve three separate private placements in
the total amount of NOK 165,394,048.50 ("The Private Placements")
and a subsequent offering (The Subsequent Offering). Following
completion of The Private Placements the Company will issue
110,262,699 new shares, bringing the total number of outstanding
shares in HBC to 232,472,269 shares (prior to completion of the
Subsequent Offering). The subscription price in The Private
Placements was NOK 1.50 per share.
This notice serves as a
combined notice of disclosure of large shareholdings and notice of
subscription from primary insiders, as further described
below.
Subscription by primary
insiders
The following primary
insiders have subscribed for and been allocated new shares in The
Private Placements resolved today:
- Roger Hofseth AS, a
company directly controlled by the Chairman of the Board in HBC,
Mr. Roger Hofseth, has subscribed for 12,216,592 new shares which
will bring Roger Hofseth AS' total shareholding, including a
forward contract for 3,850,000 shares, upon registration of The
Private Placements issue (but prior to completion of the Subsequent
Offering), to 37,047,701 shares, corresponding to 15.94% of the
total share capital. For Roger Hofseth AS this also serves as
disclosure of large shareholdings.
- Dr. Bomi Framroze,
Chief Scientific Officer, has subscribed for 313,516 new shares
which brings his total shareholding upon registration of the
Private Placements (but prior to completion of the Subsequent
Offering), to 786,630 shares, corresponding to 0.34% cent of the
total share capital;
Disclosure of large
shareholdings
In the Private Placements,
the following subscribers surpassed a threshold for disclosure of
large shareholdings:
- Deep Blue Ventures on
behalf of DBVF 1 Segregated Portfolio subscribed for 39,122,672 new
shares which will give them a total shareholding in the Company of
16.83%, upon registration of the Private Placements issue (but
prior to completion of the Subsequent Offering). Following The
Private Placements, Deep blue Ventures will own 39,122,672 shares
in the Company.
- Alliance Seafoods
subscribed for 33,333,333 new shares which will give them a total
shareholding in the Company of 14.34%, upon registration of the
Private Placements issue (but prior to completion of the Subsequent
Offering). Following The Private Placements, Alliance Seafoods will
own 33,333,333 shares in the Company.
- Hofseth International
AS (including associated companies hereunder Hofseth AS, Seafood
Farmers of Norway AS and Hofseth Logistics AS) subscribed for
25,150,586 new shares and thus increased their total shareholding
in the Company to 19,90%, including shares held by abovementioned
associated companies. Hofseth AS has decreased their shareholdings
to 9.15% and Hofseth International AS has increased their
shareholdings to 8.18%. Following The Private Placements, Hofseth
International AS (and associated companies) holds a total
shareholding of 46,261,981 shares in the Company.
- As a consequence of
the Private Placements, the shareholding of Jan Pettersson (and
associated companies) in the Company has decreased to 4.79%.
Following the Private Placements, Jan Pettersson (and associated
companies) still own 11,142,657 shares in the Company.
For further information,
please contact:
Jon Olav Ødegård, CFO Hofseth BioCare ASA
Tel: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare
ASA:
HBC is a Norwegian biotech
company that offers high-value ingredients and finished products
for humans and pets. The company is founded on the core values of
sustainability, traceability and optimal utilization of natural
resources. Through an innovative hydrolysis technology, HBC is able
to preserve the quality of salmon oil, proteins and calcium,
prepared of fresh salmon off-cuts. HBC's objective is to contribute
to the efficient use of marine resources and deliver quality
products for ingredients and finished consumer products in the
nutrition market.
Hofseth BioCare's
headquarters are located in Ålesund, Norway with branches in Oslo,
Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange
Axess list with ticker "HBC". More information about Hofseth
BioCare at www.hofsethbiocare.com and
www.facebook.com/hofsethbiocare
This information is subject
to the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.